Back20/20 Biolabs Common Stock Overview

20/20 Biolabs Common Stock Total Liabilities

Latest total liabilities for AIDX: $410K.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$412641.00

Peer trimmed avg / median

Loading

20/20 Biolabs Common Stock Total Liabilities History

Loading

20/20 Biolabs Common Stock vs. peers: Total Liabilities Comparison

Loading

20/20 Biolabs Common Stock Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

20/20 Biolabs Common Stock (AIDX) FAQ

As of the most recent data (June 2026), AIDX shows a total liabilities of $410K. Scroll down for historical charts and peer comparison views.

Tracking AIDX's total liabilities over time shows whether 20/20 Biolabs Common Stock is scaling, shrinking, or reshaping that part of the business. The current reading is $410K Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has 20/20 Biolabs Common Stock's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $410K) with ownership activity and broader fundamentals.